Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys.
Fenwick, C., Turelli, P., Duhoo, Y., Lau, K., Herate, C., Marlin, R., Lamrayah, M., Campos, J., Esteves-Leuenberger, L., Farina, A., Raclot, C., Genet, V., Fiscalini, F., Cesborn, J., Perez, L., Dereuddre-Bosquet, N., Contreras, V., Lheureux, K., Relouzat, F., Abdelnabi, R., Leyssen, P., Levy, Y., Pojer, F., Le Grand, R., Trono, D., Pantaleo, G.(2023) J Infect 87: 524-537
- PubMed: 37852477 
- DOI: https://doi.org/10.1016/j.jinf.2023.10.008
- Primary Citation of Related Structures:  
8PQ2, 8PSD - PubMed Abstract: 
Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to vaccine-induced humoral immunity and the near complete loss of protective efficacy of licensed therapeutic monoclonal antibodies, we isolated a potent, broad-spectrum neutralizing antibody that could potentially provide prophylactic protection to immunocompromised patient populations.
Organizational Affiliation: 
Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.